Dr. Bast is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161Fax+1 713-792-7864
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1976 - 1977- Brigham and Women's HospitalResidency, Internal Medicine, 1975 - 1976
Johns Hopkins UniversityInternship, Internal Medicine, 1971 - 1972
Harvard Medical SchoolClass of 1971
Certifications & Licensure
FL State Medical License 2021 - Present
AZ State Medical License 2023 - 2026
AL State Medical License 2023 - 2025
MA State Medical License 1976 - 2025
MS State Medical License 2023 - 2025
NC State Medical License 1984 - 2025
OK State Medical License 2020 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
- Join now to see all
Awards, Honors, & Recognition
- Whos Who in United States Marquis Whos Who
- Fellow American Scocirty of Clinical Oncology, 2017
- Fellow American Association for the Advancement of Science, 2002
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsCrizotinib Enhances PARP Inhibitor Efficacy in Ovarian Cancer Cells and Xenograft Models by Inducing Autophagy.Janice M Santiago-O'Farrill, Alicia Blessing Bollu, Hailing Yang, Vivian Orellana, Marc Pina
Molecular Cancer Research. 2024-09-04 - A metabolite-based liquid biopsy for detection of ovarian cancer.Johannes F Fahrmann, Seyyed Mahmood Ghasemi, Chae Y Han, Ranran Wu, Jennifer B Dennison
Biomarker Research. 2024-08-28 - 3 citationsDIRAS3 induces autophagy and enhances sensitivity to anti-autophagic therapy in KRAS-driven pancreatic and ovarian carcinomas.Gamze Bildik, Joshua P Gray, Weiqun Mao, Hailing Yang, Rumeysa Ozyurt
Autophagy. 2024-03-01
Journal Articles
- Paclitaxel Sensitivity of Ovarian Cancer Can Be Enhanced by Knocking down Pairs of Kinases That Regulate MAP4 Phosphorylation and Microtubule StabilityRobert C Bast, Anil K Sood, Clinical Cancer Research
Press Mentions
Green3Bio Announces Publication of Pre-Clinical Data Demonstrating SIK2 Inhibition (Including GRN-300) Enhances PARP Inhibitor Activity Synergistically in Ovarian and Triple Negative Breast CancersJune 24th, 2022
MD Anderson Receives $55 Million over Five Years in Comprehensive Cancer Center Status RenewalAugust 22nd, 2019
NFCR Fellow Susan Band Horwitz Named Giant of Cancer CareJune 3rd, 2019- Join now to see all
Grant Support
- The University Of Texas M. D. Anderson Cancer Center Spore In Ovarian CancerNational Cancer Institute2010–2011
- P1 - Early Detection Of Epithelial Ovarian CancerNational Cancer Institute2010–2011
- ARHI (Diras 3) In Autophagy And Dormancy Of Ovarian CancerNational Cancer Institute2009–2011
- PAUL Calabresi Clinical Oncology AwardNational Cancer Institute2005–2011
- Early Detection Of Epithelial Ovarian CancerNational Cancer Institute2008–2009
- University Of Texas MD Anderson Spore In Ovarian CancerNational Cancer Institute2000–2009
- Developmental Research ProgramNational Cancer Institute1999–2009
- Career Development ProgramNational Cancer Institute1999–2009
- Clinical Oncology Research Career Development ProgramNational Cancer Institute2000–2004
- Specific Immunotherapy With Monoclonal AntibodiesNational Cancer Institute1995–2004
- Training For Academic OncologyNational Cancer Institute1999–2003
- Core--Planning And EvaluationNational Cancer Institute2001–2002
- ARHI: An Imprinted Tumor Suppressor GeneNational Cancer Institute2001–2002
- Chemoprevention Of Ovarian Cancer With Fenretinide And Oral ContraceptivesNational Cancer Institute1999–2002
- Chemoprevention Of Ovarian Cancer In Women Using Fenretinide/Oral ContraceptivesNational Cancer Institute1999–2002
- Y2, A Novel Ovarian Cancer Tumor Suppressor GeneNational Cancer Institute1998–2000
- Spore In Ovarian CancerNational Cancer Institute1999
- Training For Academic Oncology/HematologyNational Cancer Institute1996–1998
- Core--Developmental FundsNational Cancer Institute1996–1998
- Immunodetection And Immunopharmacologic Elimination Of Breast/Ovarian CancerNational Cancer Institute1996–1997
- Training For Academic Oncology/HematologyNational Cancer Institute1995
- Clinical Cancer Research ProgramNational Cancer Institute1985
Committees
- Member, Expert Panel, American Society of Clinical Oncology (ASCO) 2015 - Present
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
